Molbio Diagnostics Ltd

Q1 FY27Healthcare Equipment & Supplies

Molbio Diagnostics Ltd Q1 FY27 Results & Concall Highlights: Capex ₹72 Cr

Q1 FY27 earnings call: what management guided on revenue, margins and order book.

Price₹1,288

Market cap₹16.6K Cr

P/E66.4

Updated18 Sept 2026

Read5 min read

What the Q1 FY27 call signalled

2 of 3 strong

RevenueRank 2

MarginRank 3

CapexYes

Not discussed on this call: fundraise, order book.

The short version

Expecting roughly 25% top-line growth for FY27, driven by increasing device and test kit sales. - Test kit volumes are increasing significantly, with Q1 FY27 kits volumes higher than Q4 FY26, indicating strong recurring revenue growth. - Device sales expected to remain steady, historically ranging between 2,200 to 2,600 units annually. - Export business ramping up aggressively, expanding in over 90 countries including LMICs and developed markets (Europe, US). - New product rollouts such as Truenat HPV and OptraScan (recent U.S. Molbio Diagnostics is targeting roughly 25% top-line growth for FY27.

From Molbio Diagnostics Ltd's Q1 FY27 earnings-call transcript · updated 18 Sept 2026.

Revenue & Sales Performance

Rank 2

Expecting roughly 25% top-line growth for FY27, driven by increasing device and test kit sales.
Test kit volumes are increasing significantly, with Q1 FY27 kits volumes higher than Q4 FY26, indicating strong recurring revenue growth.
Device sales expected to remain steady, historically ranging between 2,200 to 2,600 units annually.
Export business ramping up aggressively, expanding in over 90 countries including LMICs and developed markets (Europe, US).
New product rollouts such as Truenat HPV and OptraScan (recent U.S. FDA approval) expected to open up new large revenue streams over the medium term.
Capacity utilization currently at ~58% for test kits and ~42% for devices; automation capex will double revenue capacity with minimal new investment.
Long-term TB business expected to grow as government shifts from microscopy to molecular diagnostics.
Overall growth supported by continuous R&D investment (~5-6% of revenue) and strategic partnerships.

Profitability & Margins

Molbio Diagnostics is targeting roughly 25% top-line growth for FY27.
EBITDA margin guidance for FY27 is expected to be around 24% to 25%.
Profit After Tax (PAT) for Q1 FY27 was 13% of revenue; potential for improvement as business stabilizes.
Prognosys is expected to deliver similar margins (~19% EBITDA) in FY27 as last year.
OptraScan is currently loss-making but fully funded and expected to grow post US FDA approval; profitability may take time.
Export business is expected to ramp up and become a significant growth driver in coming years.
R&D will continue at 5-6% of revenue to drive innovation and expand test offerings.
Capacity expansion via automation is expected to enable doubling of revenue without major additional capex.
Overall, growth will be led by expanding geographies, test menu, and recurring kit sales.

See what Molbio Diagnostics Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Yes

₹200 crores raised in the IPO for automation and infrastructure.
₹72 crores allocated for automation to increase efficiency and capacity, enabling up to 2x revenue growth without major new capex.
₹105 crores planned for building an integrated R&D center in Bangalore to consolidate over 150 scientists and support staff.
No major capex expected for expanding manufacturing capacity; current utilization is 58% for test kits and 42% for devices.
Any manufacturing consolidation (e.g., Goa facility) will be funded through internal accruals.
Strategic investments: The company runs the "Edge program" to partner with MedTech startups, potentially leading to licensing, tie-ups, or strategic investments (e.g., partnership with UE LifeSciences for breast health scanners).

Top-ranked in Healthcare Equipment & Supplies

Ranked on what management guided this quarter

5x potential

1OSEL Devices Ltd₹663 Cr

Rev 1Mar 3

2Vaidya Sane₹168 Cr

Rev 2Mar 1

3₹175 Cr

Rev 2Mar 3

4₹677 Cr

Rev 3Mar 2

5₹17.6K Cr

Rev 3Mar 3

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

Molbio Diagnostics has raised ₹200 crores through IPO proceeds.
Approximately ₹72 crores of the IPO funds are allocated for automation to increase efficiency and capacity.
Around ₹105 crores from IPO proceeds will be used to build an integrated R&D center in Bangalore.
The company does not see any requirement for major additional capex beyond the existing plans and expects to fund any minor facility consolidations through internal accruals.
For OptraScan (acquired via a fresh infusion of about USD 30 million), the business is fully funded with no anticipated need for additional capital over the next 2 to 3 years.
No explicit mention of upcoming fundraising through debt or equity beyond these points was made in the call transcript.

See what Molbio Diagnostics Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The transcript does not provide explicit details on the current or expected order book or the pending orders for Molbio Diagnostics Limited as of Q1 FY27. However, relevant insights from the call include: - Export orders experienced some deferrals, e.g., a certain order shifted from FY26 to Q1 FY27, contributing to fluctuations in export revenue. - Export business is stabilizing across 90 countries with ongoing registrations, indicating a growing international order pipeline. - Government tenders, such as for HPV test kits in India, have completed validation, and rollout into national programs is expected soon, implying potential sizable order inflows. - Discussions with large laboratories for OptraScan in the U.S. have started post-FDA approval, which may translate into future orders. - No specific quantitative order backlog numbers or pending order values were disclosed on the call.

Others in Healthcare Equipment & Supplies this season

QMS Medical Allied Services Ltd (Q1 FY27)
Contract renewals historically exhibit a 60-70% roll-over rate annually, ensuring revenue visibility from existing clients. Key concall takeaways from QMS…
Laxmi Dental Ltd (Q1 FY27)
PAT grew 23.8% y-o-y in Q1 FY27, showing healthy bottom-line growth (Page 4). Key concall takeaways from Laxmi Dental Ltd's Q1 FY27 earnings call — and how it…
Prevest Denpro Ltd (Q1 FY27)
Digital dentistry revenue, especially 3D printing resins, grew 40% this year; 3D printer sales rose by 162%, indicating strong growth potential, with plans for…
Vasa Denticity Ltd (Q1 FY27)
Average order value increased by about 27% largely due to higher ticket-size products; order volume growth was around 8% (Page 6). Key concall takeaways from…

Compare:vs Poly Medicure Ltd vs Fischer Medical Ventures Ltd vs Tarsons Products Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Molbio Diagnostics Ltd Q1 FY27 results?

What is Molbio Diagnostics Ltd share price analysis?

Molbio Diagnostics Ltd currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 66.4 with a market cap of ₹16,574 Cr. Investors should review the full earnings analysis for detailed insights.

Is Molbio Diagnostics Ltd planning capital expenditure?

₹200 crores raised in the IPO for automation and infrastructure.

Keep Molbio Diagnostics Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.